521 completed, 168 unknown, 143 recruiting, 104 terminated. 1103 Phase 3, 169 Phase 2.
Follow Lymphatic Diseases: new trials by email Literature Review of Lymphatic Diseases trials Research Report on Lymphatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Amgen | 560 | 2028-06-30 | 2026-09-15 |
| Astragalus for Symptomatic Alleviation in High-grade Lymphoma Astragalus, Placebo - High-grade Lymphoma | Phase 3 | Not yet recruiting | Bnai Zion Medical Center | 60 | 2027-08-01 | 2026-09-30 |
| A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma Surovatamig, Involved Site Radiotherapy (ISRT), Involved-Site Radiotherapy (ISRT) + Rituximab - Follicular Lymphoma | Phase 3 | Not yet recruiting | Australasian Leukaemia and Lymphoma Group | 140 | 2027-01-12 | 2026-09-30 |
| Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization rhTPO prophylaxis plus EAP stem-cell mobilization - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 70 | 2027-01-01 | 2026-09-30 |
| A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5 Surovatamig, Rituximab, Cyclophosphamide - Large B-cell Lymphoma | Phase 3 | Not yet recruiting | AstraZeneca | 1200 | 2026-12-22 | 2026-11-02 |
| A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) MK-1045, Zilovertamab vedotin, Rituximab - Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 470 | 2026-12-13 | 2026-11-05 |
| Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders AZ-3102 - Niemann-Pick Disease Type C, GM2 Gangliosidosis | Phase 2 / Phase 3 | Not yet recruiting | Azafaros B.V. | 218 | 2026-12-10 | 2026-10-21 |
| Evaluation of Iopofosine I 131 vs. R-CD in WM Patients Iopofosine I 131, Rituximab (active comparator), Cyclophosphamate - Waldenstrom Macroglobulinaemia, Waldenstrom Macroglobulinemia | Phase 3 | Not yet recruiting | Cellectar Biosciences, Inc. | 219 | 2026-12-01 | 2026-08-14 |
| Evaluation of the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis Prednisone, Compound betamethasone - Sarcoidosis, Pulmonary | Phase 2 / Phase 3 | Not yet recruiting | Peking Union Medical College Hospital | 126 | 2026-11-01 | 2026-10-15 |
| Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease IVIG, Aspirin, Firsekibart - Kawasaki Disease | Phase 2 / Phase 3 | Not yet recruiting | Children's Hospital of Fudan University | 90 | 2026-11-01 | 2026-10-22 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Efficacy of Short Course of Intravenous Dexamethasone and Intravenous Immunoglobulin Therapy in Infection-Related Secondary Hemophagocytic Lymphohistiocytosis (isHLH) Intravenous Immunoglobulin (IVIg) therapy, Intravenous Dexamethasone (IVD) therapy, Targeted antimicrobial therapy & standard care - Hemophagocytic Lymphohistiocytosis (HLH), Secondary Hemophagocytic Lymphohistiocytosis | Phase 3 | Not yet recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 116 | 2026-10-15 | 2026-10-06 |
| A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma JS203 in combination with gemcitabine and oxaliplatin, Rituximab in combination with gemcitabine and oxaliplatin - Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 282 | 2026-10-08 | 2026-10-14 |
| A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL). ICP-248, Pirtobrutinib, Orelabrutinib - Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Phase 3 | Not yet recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 280 | 2026-10-01 | 2026-08-25 |
| Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma Orelabrutinib, ICP-248 - Relapsed/Refractory Marginal Zone Lymphoma (MZL) | Phase 3 | Not yet recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 292 | 2026-10-01 | 2026-10-27 |
| Better Options for Lymphatic Filariasis Treatment MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole, IDA - Ivermectin + DEC + albendazole - Lymphatic Filariasis, Scabies | Phase 3 | Recruiting | Medicines Development for Global Health | 5100 | 2026-09-28 | 2026-10-07 |
| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency | Phase 3 | Recruiting | CSL Behring | 63 | 2026-09-15 | 2026-10-14 |
| International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) Inotuzumab ozogamicin (INO), Blinatumomab - B-Cell Acute Lymphoblastic Leukaemia | Phase 3 | Recruiting | Charite University, Berlin, Germany | 750 | 2026-09-01 | 2026-10-26 |
| Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) Birelentinib, Rituximab, Cyclophosphamid - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 / Phase 3 | Not yet recruiting | Dizal Pharmaceuticals | 880 | 2026-09-01 | 2026-08-05 |
| Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma Immunoglobulin, antibiotic prophylaxis - Chimeric Antigen Receptor T-cell Therapy, B Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 228 | 2026-09-01 | 2026-08-10 |
Showing 20 of 1103. Sign in to see all of them.
Lymphoma (225) · Lymphoma, Follicular (218) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (198) · Lymphoma, Large B-Cell, Diffuse (185) · Lymphoma, Non-Hodgkin (183) · Leukemia, Lymphocytic, Chronic, B-Cell (176) · Leukemia (112) · Hodgkin Disease (96) · Lymphoma, Mantle-Cell (86) · Burkitt Lymphoma (76) · Lymphoma, B-Cell, Marginal Zone (71) · Leukemia, Myeloid, Acute (67) · Multiple Myeloma (61) · Recurrence (56) · Neoplasms (54)
Hemic and Lymphatic Diseases (1103) · Immune System Diseases (1003) · Lymphoproliferative Disorders (980) · Neoplasms by Histologic Type (956) · Immunoproliferative Disorders (951) · Neoplasms (923) · Lymphoma (465) · Hematologic Diseases (444) · Lymphoma, Non-Hodgkin (386) · Leukemia, Lymphoid (360) · Pathological Conditions, Signs and Symptoms (295) · Leukemia (287) · Pathologic Processes (274) · Disease Attributes (245)
Rituximab (265) · Cyclophosphamide (227) · Vincristine (180) · Doxorubicin (166) · Prednisone (147) · Etoposide (100) · Cytarabine (98) · Methotrexate (97) · Dexamethasone (90) · Radiotherapy (73) · Bendamustine Hydrochloride (67) · Mercaptopurine (54) · Filgrastim (46) · Lenalidomide (46) · Prednisolone (45)
Children's Oncology Group (34) · Hoffmann-La Roche (31) · Assistance Publique - Hôpitaux de Paris (22) · National Cancer Institute (NCI) (20) · European Organisation for Research and Treatment of Cancer - EORTC (19) · Novartis Pharmaceuticals (19) · Pfizer (15) · Fondazione Italiana Linfomi - ETS (14) · Celgene (12) · German CLL Study Group (12) · Ruijin Hospital (12) · Alliance for Clinical Trials in Oncology (11) · Amgen (11) · Gilead Sciences (11) · Lymphoma Study Association (11)
United States (487) · France (280) · Italy (247) · United Kingdom (247) · Germany (246) · Canada (234) · China (226) · Australia (214) · Spain (213) · Belgium (188) · Poland (180) · Czechia (133) · Netherlands (133) · Israel (122) · Austria (119)
Michael Hallek, MD (7) · Matthew Krebs, Dr (5)
PMID 40135712, PMID 39121442, PMID 32632956, PMID 32816215, PMID 33242441, PMID 37505794, PMID 38620092, PMID 26373676, PMID 28751558, PMID 33288485, PMID 37890117, PMID 39563886, PMID 40266025, PMID 41671463, PMID 11873261, PMID 22610930, PMID 27282998, PMID 30010775, PMID 31196847, PMID 32228663, PMID 33131249, PMID 34515338, PMID 34865212, PMID 37341189, PMID 38446568, PMID 38502198, PMID 41074963, PMID 42699559, PMID 10656038, PMID 11807147, PMID 15812540, PMID 16754935, PMID 20032498, PMID 20679620, PMID 21195303, PMID 23065509, PMID 23233721, PMID 24687837, PMID 24797299, PMID 24916506, PMID 24970932, PMID 25103870, PMID 25753432, PMID 26149717, PMID 26590194, PMID 27695295, PMID 28396102, PMID 29255066, PMID 29284596, PMID 29880603
2023 (32), U10CA098543 (18), 2015 (14), 2016 (12), 2009 (11), U10CA180886 (11), 2014 (10), 2017 (9), 2025 (9), 2008 (8), 2019 (8), U10CA032102 (6), U01HL069294 (5), U10CA021115 (5), U10CA180820 (5)